Eli Lilly Financials

Eli Lilly and Co

LLYNYSE

$1162.43

2.430.21%

마지막 업데이트: Sep 2, 12:19 PM

인수합병: Merida Biosciences, Inc. announced it will be acquired by Eli Lilly (LLY) on Monday, August 31, 2026 for $2.9B paid in cash

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

Eli Lilly Financials

Eli Lilly (LLY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

The CNN Money Fear and Greed index showed improvement in market sentiment on Wednesday, while Dow Jones surged to a record high driven by strong earnings.

Avi Kapoor

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.

Vandana Singh

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown.

Vandana Singh

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Dow and S&P 500 indices hit new all-time highs, Treasury Sec. Bessent says Iran deal may reopen Strait of Hormuz.

Benzinga Neuro

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

Eli Lilly (NYSE:LLY) narrows FY2026 Adj EPS guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 analyst estimate. Raises FY2026 sales outlook from $82.000 billion-$85.000 billion to $85.000 billion-$87.000 billion vs

Benzinga News-desk

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

Eli Lilly (NYSE:LLY) reported quarterly earnings of $8.38 per share which beat the analyst consensus estimate of $6.01 by 39.43 percent. This is a 32.81 percent increase over earnings of $6.31 per share from the same

Benzinga Newsdesk

Eli Lilly and Co

Eli Lilly Financials

Earnings & Guidance News

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

뉴스

파트너 / 기고자

벤징가 글로벌

Benzinga

Benzinga

Benzinga

Eli Lilly and Co

Eli Lilly Financials

Earnings & Guidance News

Dow Hits New All-Time High: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone

Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion

CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

PROEli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate

Benzinga

뉴스

파트너 / 기고자

벤징가 글로벌

PRO
Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate